This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5: (11) International Publication Number: **WO 92/04**009 A1 A61K 9/127 (43) International Publication Date: 19 March 1992 (19.03.92)

(21) International Application Number: PCT/GB91/01547 (74) Agent: GILL JENNINGS & EVERY; 53/64 Chancery Lane, London WC2A 1HN (GB). (22) International Filing Date: 10 September 1991 (10.09.91)

10 September 1990 (10.09.90) GB (71) Applicant (for all designated States except US): SCHOOL OF PHARMACY, UNIVERSITY OF LONDON [GB/

10 September 1990 (10.09.90) GB

GB]; 29/39 Brunswick Square, London WC1N 1AX (GB). (72) Inventor: and

(75) Inventor/Applicant (for US only): GREGORIADIS, Gregory [GB/GB]; "Crantock", Kewferry Hill, Rickmansworth Road, Northwood, Middlesex HA6 2RQ (GB).

(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.

Published

With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: LIPOSOMES

(30) Priority data:

9019726.0

9019729.4

(57) Abstract

Novel liposomes have a mean diameter not exceeding 200 nm and containing at least 33 mg of one or more entrapped substances per g liposome-forming material. They may also comprise, co-entrapped or covalently linked in the same liposome, a synthetic peptide and an adjuvant which potentiates the immunogenicity of the peptide. The liposomes are useful in vaccines.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphiets publishing international applications under the PCT.

AT	Austria	· ES	Spain	MC	Moderascar
ΑÜ	- Australia	PI	Finland	ML.	Mili
	Barhados .	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
8F	Burkina Faso	GB	United Kingdom	MW	Mulawi
BC	Bulgaria	GN	Guinca	NL	Netherlands
BJ	Benin	GR	Grucec	NO	Norway
BR	Bravil	HU	Нипрагу	PL	Poland
CA	Canada	IT -	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CC	Congo	KP	Democratic People's Republic	SE	Sweden
CII	Switzerland	•••	of Korea	SN	
CI	Côte d'Ivoire	KR	Republic of Korca	SU+	Senegal Soviet Union
CM	Cameroon	LI	Liechtenstein	TD	Chad
CS	Czechoslovakia	LK	Srl Lanka		
DE.	Germany	LU	Luxemboure	TC	Togo
DK	Dunmark	MC	Massa	US .	United States of America

⁺ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

35

1

LIPOSOMES

Field of the Invention

The present invention relates to liposome preparations which combine small size with very high retention of added substances. The present invention also relates to liposomes containing synthetic peptides, e.g. for use in vaccines.

Background of the Invention

High efficiency entrapment (retention) of substances using minimal amounts of lipid is a prerequisite for the 10 effective use of liposomes in a variety of applications. For example, a high entrapped drug to lipid mass ratio is necessary for an acceptable cost of formulation and an acceptable low risk of lipid-induced toxicity 15 pharmaceutical use. Unfortunately, current liposome preparations and methodologies giving high efficiency entrapment, as described by Szoka et al, Proc. Nat. Acad. Sci. USA 75 (1978) 4194-4198, and by Kirby and Gregoriadis, Biotechnology 11 (1984) 979-984, result in large liposomes, having mean diameters approaching 1 μm in size. This large 20 size severely limits, for example, pharmaceutical use: such large liposomes, on intravenous injection, exhibit short half-lives in blood circulation; see Senior et al, Biochim. Biophys. Acta <u>839</u> (1985) 1-8. They are therefore unsuitable for maintaining increased concentrations of 25 drugs and other substances within the vascular system. In addition, such large liposomes are unsuitable for use as delivery systems for targeting of drugs or other substances to specific sites, for example to diseased cells in the 30 body.

Smaller liposomes, 200 nm or less in diameter, are considerably more stable, for example in the bloodstream, than the larger liposomes described above. Other features of smaller liposomes for pharmaceutical applications are that, unlike larger liposomes, they are able to reach the lymph nodes efficiently and to deliver vaccines and other agents to these sites: see Senior et al, loc. cit.; Turner

et al, Biochim. Biophys. Acta 760 (1983) 119-125; Allen et al, FEBS Letters 223 (1987) 42-46; Chow et al, Pharmacol. Exper. Ther. 248 (1989) 506-513; and Spanzer et al, Biochim. Biophys. Acta 836 (1986) 224-230. However, current techniques for preparing small liposomes, as described by Mayhew et al, Biochim. Biophys. Acta 775 (1984) 169-174, suffer from either a low efficiency of entrapment of substances or from a large lipid requirement (180 μmol per ml or greater) for efficient entrapment.

Most current vaccine preparations for infectious 10 disease comprise either attenuated or killed infectious Such preparations suffer from problems such as safety, for example reversion of attenuated to virulent and lack of effectiveness, for example an strains. 15 incidence non-responsive recipients. of widespread interest in the possibility of synthetic peptide vaccines, especially against viral, bacterial and parisitic diseases (see Arnon, Synthetic Vaccines, 1987 (vols. 1 and 2), CRC Press Inc.) and, more recently, in cancer. The principle of a synthetic peptide vaccine is that the 20 protective epitopes on, for example, infectious agents are copied as short synthetic peptides free of any infectious agent. In order to be effective, a synthetic peptide must possess a high level of immunogenicity and antibodies which cross-react extensively with the target 25 organism or cell; see Van Regenmortel, Immunology Today 10 (1989) 266-272. In practice, peptides alone tend to possess weak immunogenicity, and anti-peptide antibodies often do not recognise the native protein antigen; see Jemmerson et al, Molecular Immunology 26 (1989) 301-307. 30

A common method for enhancing the immunogenicity of synthetic peptide epitopes is to combine the peptides with an immunological adjuvant. Adjuvants are agents which provoke potent immune responses to antigens, and include aluminium hydroxide (alum), saponins, pluronic polymers with mineral oil, killed mycobacterium in mineral oil (Freund's complete adjuvant), bacterial products such as

15

25

muramyl dipeptide, and immunogenic carrier proteins such as tetanus toxoid. Adjuvants, depending on their nature, induce humoural (HI) and/or cell-mediated immunity (CHI). However, most of such adjuvants are either unsuitable for combination with peptides, have toxic side-effect problems, or fail to induce both HI and CMI; see Gregoriadis, Immunology Today 11 (1990) 89-97. A further problem is interference of peptide immunogenicity by immune response to a carrier protein; see Etlinger et al, Science 249 (1990) 423-425.

As described elsewhere (see Gregoriadis, loc. cit.), liposomes have the potential for a safe and effective adjuvant for peptide vaccines, and the immunopotentiation of a number of synthetic peptides has been shown. However, such immunopotentiation by liposomes is not a general phenomenon. For example, liposomal immunopotentiation has not been observed with a pre-S peptide (amino acids 15-48) from Hepatitis B surface antigen (HBsAg) or with a 3VP2 peptide from poliovirus.

Summary of the Invention 20

Novel, small liposomes have a mean diameter less than 200 nm and high entrapment efficiency, and require low (<150 μ mols per ml) concentrations of starting lipid. They are suitable for use in a variety of applications, including, for example, cosmetics for the sub-epidermal delivery of substances by liposomes, medical diagnostics for the stable entrapment of easily measurable substances, and pharmaceuticals (as described above).

Further, novel synthetic peptide vaccine preparations comprise liposomes containing entrapped or covalently-30 · linked peptides together with molecules which augment the immune response to the peptides.

Description of the Invention

Examples of substances that may be entrapped in liposomes of the invention are pharmaceuticals, vaccines, 35 materials, enzymes, hormones, vitamins, carbohydrates, proteins/peptides, lipids,

15

20

molecules, and inorganic molecules or atoms. More spacific examples are anti-tumour and anti-microbial agents, enzymes, hormones, vitamins, metal chelators and genetic material, preferably carbohydrates or proteins/peptides. The liposomes may be incorporated into vaccines.

The liposomes may be produced from one or more of phosphatidylcholine, cholesterol, phosphatidylglycerol, phosphatidylethanolamine, phosphatidylserine, phosphatidic sphingomyelin or derivatives of these lipids, preferably phosphatidylcholine or cholesterol. The process 10 for their preparation may be from a starting lipid concentration of less than 150 $\mu mols$ per ml, to provide an efficiency of entrapment of >10% of a starting substance concentration. The method involves a combination of the dehydration-rehydration vesicle (DRV) process (see Kirby and Gregoriadis, loc. cit.) and the microfluidation process described by Talsma et al, Drug Development Ind. Pharm. 15 (1989) 197-207. Briefly, the method involves mixing lipids with substances to be entrapped and subjecting the mixture to controlled dehydration and rehydration to form large multilamellar vesicles with high entrapment efficiency. These large vesicles are then subject to microfluidation to produce small liposomes with 10-100% retention of the entrapped substances.

25 As will be apparent from the evidence given below, microfluidisation of solute-containing DRV's in PBS and the presence of unentrapped solute produces vesicles less than 200 nm in size, and which are suitable for the given purposes. Such vesicles retain, under the present conditions, 35-78% of the originally entrapped solute. 30 Compared to procedures (Mayhew et al, loc. cit.) which employ much larger amounts of lipid to achieve efficient entrapment, the present approach provides preparations with augmented solute to lipid mass ratios and should also be more economical. The narrow distribution of final vesicle 35 sizer must reflect the nature of the production process. Whereas sonication disrupts vesicles in a random mode,

20

25

producing a wide range of diam ers, microfluidisation distorts large and flexible vesicles by extrusion through a capillary, thereby increasing the number of vesicles of similar size which "bud off" from simple parent vesicles.

While being applicable across the broad range of the invention, the minimum amount of retained solute is 35%, i.e. 2.5 mg with respect to a starting amount of 7.2 mg of the relevant substance. This is for up to 66 µmoles, i.e. up to 50 mg, phosphatidylcholine (approximate molecular weight 760) up to 25 mg cholesterol (molecular weight 387). Therefore, by means of the present invention, it is possible to produce liposomes having mean diameters of less than 200 nm which contain at least 50 mg of the entrapped substance per g phospholipid or at least 33 mg of the substance per g of liposome-forming materials. In Example 1, the liposomes retain approximately 35-78% of the originally entrapped test substances maltose or tetanus toxoid (herein referred to as solutes) following microfluidisation. This corresponds to an overall solute entrapment yield of >10%.

For example when including one or more adjuvants, liposome preparations are made by standard methods for producing liposomes, for example as described by Gregoriadis, ed., Liposome Technology (1984) vols. 1 to 3, CRC Press Inc. In such methods, liposome components, peptides and adjuvant molecules are either mixed or covalently linked prior to formation of liposomes.

The following Examples illustrate the invention, with reference to literature articles given above and also to Deamer and Uster, Liposome Preparation: Methods and mechanisms in: ed. Ostro, Liposomes, M-rcel Dekker, Inc., New York, 1983, pp 27-51; Gregoriadi. et al, Vaccine 5 (1987) 145-151; and Davis and Gregoriadis, Immunology 61 (1987) 229-234.

The source and grades of egg phosphatidylcholine (PC) and cholesterol have been reported elsewhere (Kirby and Gregoriadis, 1984). Maltose was from Sigma Chemical

Company (London) and immunopurified tetanus toxoid from Wellcome Biotechnology (Beckenham). D-[U- 14 C]-maltose (20 GBq per μ mol) was purchased from Amersham International (Amersham, U.K.) and toxoid-labelled (specific activity 5.43 mBq) with 125 I as described elsewhere (Gregoriadis et al, 1987).

The following abbreviations are used:

60 psi = 414 kPa

PBS - Phosphate-Buffered Saline

10 PC - Phosphatidylcholine

DRV - Dehydration-Rehydration Vesicles

SUV - Small Unilamellar Vesicles

dpm - disintegration per minute

Example 1

15 Preparation of liposomes

Solute-containing DRV liposomes were prepared by the procedure discussed elsewhere (Kirby and Gregoriadis, 1984; Gregoriadis et al, 1987). Briefly, small

unilamellar vesicles (SUV) made in distilled water from equimolar PC (16.5, 33, 65 or 132 µpol) and cholesterol were mixed with an equal volume (2.0 ml) of maltose (7.2 mg) or tetanus toxoid (7.2 mg) dissolved in PBS (0.44mM sodium phosphate, 2.7mM potassium chloride and 0.14 M sodium chloride, pH 7.4) and supplemented with traces (4.9 \times 10 - 8.7 \times 10. dpm) of the respective rediclabelled solutes. Following dehydration and controlled (Kirby and Gregoriadis, 1984) rehydration to form solute-containing DRV, the suspensions (2.0 ml) were each divided into two equal portions. One portion was centrifuged at 20,000g for 30 min, the pellet washed three times with PBS and suspended in 20 ml of the same buffer (washed DRV) for microfluidization. Entrapment of solutes was estimated by the assay (Kirby and Gregoriadis, 1984; Gregoriadis et al, 1987) of ¹⁶C or ¹⁸I radioactivity in the suspension, and results expressed as percentage of the solute originally present. The other portion (containing a mixture of entrapped and unentrapped solute) was also diluted in 20 ml PBS (unwashed DRV) and then microfluidized. In some experiments, PBS was replaced by distilled water in all steps involved in the entrapment of solutes in DRV and microfluidization of washed or unwashed preparations.

Microfluidization of liposomes

Washed and unwashed DRV (20 ml each) were passed for 1.8, 3.5, 5.2, 7.1 and 10.6 full cycles through a Microfluidizer 110TM kindly provided by Microfluidics Corp., Newton, MA, USA. The pressure gauge was set at 60 psi throughout the procedure to give a flow rate of 35 ml per minute. At the end of each of the 20 ml cycle intervals, samples containing maltose were dialysed exhaustively

against distilled water or PBS, and the toxoid containing vesicles or centrifuged for 30 min at 20,000g (1.8 and 3.5 cycles) or 35,000g (5.2, 7.1 and 10.6 cycles), the pellets washed twice in PBS or water and resuspended in 1.0 ml of the respective solvents. In the case of the toxoid, the supernatants obtained on centrifugation were passed (Senior et al. 1985) through Sepharose 4B columns; very little (less than 3%) of the solute in the centrifuged samples eluted in the liposome form. The extent to which washed and unwashed DRV's retained their solute content after microfluidization was estimated as follows: for washed DRV'S, radioactivity retained after dialysis or recovered in pellets after centrifugation was expressed as a percentage of the total amount in the sample before dialysis or centrifugation. Solute retention values thus obtained correspond to the percentage of the original entrapment values in the preparations before microfluidization. For unwashed DRV, the percentage of radioactivity retained after dialysis or centrifugation was expressed as % of the original entrapment values.

Measurement of vesicle size

Particle size distributions were measured by photon correlation spectroscopy of samples diluted in either water or PBS, using a Malvern Model 4700 apparatus (Malvern Instruments Ltd., Malvern, UK) equipped with a 25mW helium/neon laser. Mean diameters and size distributions are obtained: the z-average mean diameter, polydispersity factor and cumulative percentage mass and number undersize data were recorded as a function of the number of microfluidization cycles. The performance of the instrument was checked with monodisperse

polystyrene latex suspensions (Polysciences, UK) and mixtures of such latex samples to verify the ability of the system to accurately measure polydisperse or bidisperse systems.

Results and Discussion

The effect of DRV microfluidization on solute retention

As expected from previous work (Kirby and Gregoriadis, 1984; Gregoriadis et al 1987), entrapment of solutes in dehydration-rehydration liposomes was efficient, ranging from 19.2 to 66.1% of the starting material and dependent on the amount of phospholipid used (see legends to Figs 1-3). There was no significant difference in entrapment values in preparations made in distilled water or PBS (not shown). Retention values (quoted as a percentage of original entrapment values) by solute-containing DRV's microfluidized for up to 5.2 cycles in the presence of PBS are shown in Figs 1 and 2. It is apparent that retention values by both washed and unwashed DRV decrease or remain the same as the number of cycles increases (see also Fig. 3). Thus, values of 80-100% (maltose) after 1.8 cycles become 40-65% after 5.2 cycles (Fig. 1), whereas values for the toxoid (unwashed DRV) remain virtually unchanged (at around 75%) (Fig. 2). It is conceivable that during microfluidization, a process entailing breakage of the integrity/vesicle membrane and consequent leakage of entrapped solute occurs, large molecules such as proteins leak at slower rates than smaller molecules. Furthermore, no apparent difference in solute retention was observed for preparations containing varying amounts of PC (8.5-66 µmoles) (Figs. 1 and 2). Figs. 1 and 2 also indicate that, generally, a greater proportion of solute (maltose or toxoid) is retained by unwashed vesicles (ie. preparations microfluidized in the presence of unentrapped solute) than by washed DRV. The presence of unentrapped solute during microfluidization diminishes solute leakage perhaps by reducing the osmotic rupture of the vesicles and by reducing initial concentration gradients across the membrane.

The mean diameter of microfluidized DRVs measured by dynamic light scattering after a given cycle interval depended on whether the DRVs were suspended in distilled water or PBS. We therefore attempted to determine the effect of the two media on solute retention during microfluidization. Results in Fig. 3 indicate that much more maltose is retained by DRVs in the presence of PBS and similar results (not shown) were obtained with toxoid-containing DRV's under identical conditions. Such an effect of PBS presence in the milieu could be attributed to its reduction of osmotic shock expected (Kirby and Gregoriadis, 1984) to occur on dilution of solute-containing DRV in hypotonic media.

The effect of microfluidization on vesicle size

The mean diameters of washed and unwashed maltose-containing DRV microfluidized in water or PBS (from experiment described in Fig. 3), measured by photon correlation spectroscopy, are presented in Table 1. They show that, in agreement with findings by others (Talsma et al, 1989), a smaller vesicle size was achieved for preparations processed in water than in PBS. Such differences in sizes, appearing after the 1.8 cycle interval, could be attributed (Deamer and Uster, 1983) to vesicle aggregation induced by the presence of salts in the PBS

medium, but also might be due to the increased lipophilicity of the lipids in the presence of electrolyte. Reduction in the size of all preparations tested was considerable after the initial I.8 cycles interval. Subsequently, sizes levelled off to reach minimal values of 100-160 nm by 10.6 cycles depending on the medium (water or PBS) (it is of interest that a pattern similar to that of sizes in Table 1 was observed for solute retention with increasing cycle intervals (Fig.3), with values also levelling off after 3.5 cycles). Mean number diameter and mass diameter distribution data (Fig. 4 and Fig. 5) from the experiments recorded in Table I revealed a bimodal distribution of sizes in which there is an increasing number of small vesicles as the number of microfluidization cycles increases beyond the first few cycles; the mean number diameter of the sample, prepared in water (50mg maltose/water) is of the order of 300mm after 1.8 cycles, with a few vesicles with diameters up to lum in diameter. The larger diameter vesicles disappear rapidly on increasing cycling, so that after 10.6 cycles in water, a single narrow diameter (around 100 nm) distribution is obtained whereas in PBS the bimodal pattern is retained (Fig 4). However, the vesicle size distribution does not exhibit the gradual downward drift that occurs on, say, sonication but a transfer of sizes from one size band to another. In PBS, some vesicles undoubtedly flocculate so that there remains a percentage of vesicles with a high apparent diameter. Fig. 6 illustrates the distribution of diameters by mass. Here is clear evidence of the marked narrowing of the polydispersity of the vesicles. Coupled with the data from Fig. 4, this figure clearly shows the narrow distribution of sizes which is achieved after 10 cycles. Lidgate and coworkers' (1989) results show that in preparing parenteral emulsions of squalene by microfluidization, the particle size after 9-10 cycles is in the range of

0.07 to 0.2 μm which represent a much narrower distribution than other technologies.

Table 1 shows the average mean size (nm) microfluidised DRV, i.e. maltose-containing washed or unwashed DRV (33 μ moles) PC were microfluidised in the presence of water or PBS for up to 10.6 cycles and samples measured for vesicle size (diameter in nm) by dynamic light scattering (Photon correlation spectroscopy). Polydispersity indexes ranging from 0.503 to 0.653 (water) and 0.517 to 0.653 (PBS) were similar to those obtained with some of the lipid compositions of liposomes employed by Talsma et al (1987).

Table 1. z - Average mean size (nm) of microfluidised DRV

			Cycles		
DRV	1.8	3.5	5.2	7.1	10.
Washed Water PBS	463.5 447.4	149.9 198.6	115.0	121.9 159.5	114 155
Unwashed Water PBS	473.9 456.3	132.9	116.9 186.8	116.6	101 159

10

10

15

30

Description of the Drawings

Figure 1 shows entrapment values (on a scale of 0-100% of originally entrapped starting material) for 4C-labelled maltose by DRVs following microfluidisation, with respect to cycles on the abscissa. "C-maltose containing DRVs composed equimolar phosphatidylcholine of cholesterol were microfluidised in the washed (filled bars) or unwashed (shaded bars) forms in the presence of PBS for up to 5.2 cycles. Amounts of liposomal phospholipid passed through the microfluidiser were 8.25 (A), 16.5 (B), 33 (C) and 66 (D) μ mols. Values denote % retention of the originally entrapped 4C-maltose. Original entrapment values were 27.1 (A), 33.6 (B), 66.1 (C) and 65.7 (D).

Figure 2 shows entrapment values for 125 I-labelled tetanus toxoid by DRVs following microfluidisation. Details are as in Figure 1 except that amounts of liposomal phospholipid passed through the microfluidiser were 8.25 (A) and 33 (B) μ mols and original entrapment values were 19.2 (A) and 56 (B).

Figure 3 shows the effect of the liquid medium on ¹⁴Cmaltose retention by DRVs during microfluidisation.

Details are as in Figure 1 except that DRVs were
m_crofluidised 1. the presence of distilled water (A) or
PBS (B) for up to 10.6 cycles, the amount of liposomal
phospholipid passed through the microfluidiser was 33 μmols
and original entrapment values were 54.3 (A) and 55.2 (B).

Figure 4 shows the size distribution (as a percentage number) of vesicles containing maltose prepared in the presence of water as a function of the number of cycles ($\Delta = 10.6$ cycles; $\alpha = 3.5$ cycles; $\alpha = 1.8$ cycles) through the microfluidiser, showing progression to a mean distribution with a mean diameter (on the abscissa) of approximately 100 nm after 10.6 cycles.

Figure 5 is on the same basis as Fig. 4. It shows the size distribution of vesicles containing maltose prepared in the presence of PBS (50 mg maltose/PBS) as a function of the number of cycles through the microfluidiser, showing

that, after 10.6 cycles, the number of vesicles with diameters greater than 300 nm is decreased but a biphasic distribution is still maintained.

Figure 6 shows the mass distribution of vesicles containing maltose (50 mg maltose/water) as a function of cycles through the microfluidiser as in Pigure 4, showing the narrow distribution size after 10.6 cycles. Example 2

This Example shows that interleukin-2 (IL-2) acts as an effective adjuvant for the poliovirus 3-VP2 peptide when 10 entrapped with the peptide in the same liposome. mice were injected intramuscularly in groups of five on days 0 and 28 with either 5 μ g free 3-VP2 peptide, or with liposomes containing 5 μg peptide, or with liposomes containing 5 μ g peptide and 7000 Cetus units of IL-2 15 (recombinant mutein IL-2, obtained from Cetus). Liposomes were formed from equimolar distearoyl phosphatidylcholine and cholesterol using the dehydration-rehydration procedure (see Kirby and Gregoriadis, 1984). Ten days following the second injection, serum IgG antibodies specific for 3-VP2 20 peptide were estimated by ELISA assay (see Davis and Gregoriadis, 1987) whereby microtitre wells were coated with 3-VP2 peptide, diluted sera samples (1:1280 for IgG1, 1:160 for other subclasses) were added, and bound IgG's were measured through binding of IgG subclass specific 25 antibodies. The ELISA signal measured as optical density at 492 nm was produced using horseradish peroxidaselabelled second-antibody and 3,3',5,5'-tetramethylbenzidine (Miles) as substrate. Table 2 gives the results of the IgG subclass ELISA (median values underlined). Comparison by 30 Kruskall-Wallis statistical analysis of values for groups of animals receiving liposomal 3-VP2 and liposomal 3-VP2/IL-2 revealed a significant elevation of IgG levels due to the effect of IL-2 for all IgG subclasses except IgG2b. Example 3

35

SJL H-2' mice were injected intramuscularly in groups of five on days 0 and 28 with either 20 μg free pre-S

15

20

peptide or with liposomes containing 20 μ g pre-S peptide or with liposomes containing 20 μg S peptide and 20 μg pre-S Liposomes were formed from equimolar egg phosphatidylcholine and cholesterol using the dehydrationrehydration procedure (see Kirby and Gregoriadis, 1984). 5 Ten days following the second injection, serum IgG antibodies specific for pre-S peptide were estimated by ELISA assay (see Davis and Gregoriadis, 1987), whereby microtitre wells were coated with pre-S peptide, diluted samples (1:640) were added, and bound IgG; was measured through binding of IgG, specific antibodies. signal measured as optical density at 492 nm was produced using horseradish peroxidase-labelled second-antibody and 3,3',5,5' tetramethylbenzidine (Miles) as substrate. Table 3 gives the results of the IgG, subclass by ELISA (median values underlined).

Statistical analysing by Kruskall-Wallis revealed highly significant increase in IgGI response to pre-S peptide for liposomes with co-entrapped pre-S and S peptides.

Peptide ·	Secondary immune response			
formulation	IgGl	IgG ₂₈	IgC _{Zb}	IgG3
		·		
Frce 3VP2	0.086	0.074	0.075	0.125
	0.092	0.085	0.079	0.128
	0.095	0.086	0.080	0.135
•	0.096	0.113	0.080	0.141
	0.099	0.180	0.084	0.149
Liposomal 3VP2	0.110	0.100	0.079	0.151
	0.112	0.107	0.085	0.161
	0.123	0.124	0.093	0.185
٠	0.130	0.143	0.096	0.206
	0.181	0.144	0.096	0.277
Liposomal 3VP2 +				
IL-2	0.101	0.101	0.070	0.153
	0.285	0.143	0.075	0.269
	0.341	0.334	0.076	0.323
•	0.448	0.492	0.104	0.359
	1.021	0.935	0.142	0.499
Kruskall-Wallis	H=10.5	Н=5.95	H=3.64	H=10.5
(one-way)	p(0.009	0.01 <p<0.049< td=""><td>p>0.102</td><td>p<0.009</td></p<0.049<>	p>0.102	p<0.009

Peptide formulation

17

Secondary immune response to pre-S peptide

IgG₁

	· ·	
Free pre-S peptide	0.080	
	0.090	
	C 095	
	(100	
	0.100	
Liposomal pre-S peptide	0.075	
	0.080	
*	0.085	
	0.090	
	0.110	
Liposomal pre-S and	0.610	•
S peptides	0.680	•
	0.780	
· X	0.850	
	0.900	

TABLE 3.

CLAIMS

- 1. Liposomes having a mean diameter not exceeding 200 nm and containing at least 33 mg of one or more entrapped substances per g liposome-forming material.
- 5 2. Liposomes according to claim 1, wherein the one or more substances is covalently linked to a lipid component of the liposome.
 - 3. Liposomes according to either preceding claim, wherein the lipid component is one or more of phosphatidylcholine,
- cholesterol, phosphatidylglycerol, phosphatidylethanolamine, phosphatidylserine, phosphatidic acid, sphingomyelin or derivatives of these lipids.
 - 4. Liposomes according to claim 3, wherein the lipid components are phosphatidylcholine and cholesterol.
- 5. Liposomes according to any preceding claim, wherein the one or more substances are selected from carbohydrates and peptides.
- 6. Liposomes comprising, co-entrapped or covalently linked in the same liposome, a synthetic peptide and an adjuvant which potentiates the immunogenicity of the peptide.
 - 7. Liposomes according to claim 6, wherein the adjuvant is recognised by or interacts with T cells.
 - 8. Liposomes according to claim 6, wherein the adjuvant is a peptide having a T cell recognition site.
 - 9. Liposomes according to claim 6, wherein the adjuvant is IL-2.
- 10. Liposomes according to claim 6, wherein the adjuvant comprises a peptide having a T cell recognition site and 30 IL-2.
 - 11. Liposomes according to any of claims 5 to 10, wherein the peptide includes all or part of amino-acid residues 110-137 of Hepatitis B surface antigen.
- 12. Liposomes according to any preceding claim, for therapeutic use.

- 13. A vaccine composition comprising liposomes according to any preceding claim and a physiologically-acceptable excipient.
- 14. Use of liposomes according to any of claims 5 to 11, for the manufacture of a medicament for use in eliciting an immunogenic response to the synthetic peptide.
 - 15. A method for preparing liposomes having a mean diameter not exceeding 200 nm and containing one or more entrapped substances in an amount exceeding 10% of starting amounts.
 - 16. A method for producing liposomes having a mean diameter not exceeding 200 nm, comprising:
- (a) subjecting a mixture of lipid components and substances to be entrapped or covalently linked to the lipid component, to dehydration and controlled rehydration, to give large multilamellar vesicles; and
 - (b) subjecting the large multilamellar vesicles to microfluidisation.
- 17. A method according to claim 15 or claim 16, wherein the starting concentration of lipid is no more than 100 μ mols per ml.
 - 18. Liposomes according to any of claims 15 to 17, wherein the total starting concentration of all substances is no more than 10 mg per ml.
- 25 19. A method according to any of claims 15 to 18, for preparing liposomes having the characteristics of any of claims 1 to 11.

FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5





FIGURE 6



Decomensation Searched other than Minimum Documentation to the Extent that such Documents are lacinded in the Fields Searched EM. DOCUMENTS CONSIDERED TO BE RELEVANT* Category* Charico of Document, 11 with indication, where appropriate, of the relevant paragres 12 Relevant to Claim No.13 EP, A, D 290 296 (THE LIPOSOME COMPANY) 9 November 1, 3, 4, 12 1988 2,5-11, 13, 14 VACCINE vol. 5, July 1987, GUILDFORD pages 145 - 151; G. GREGORIADIS ET AL.: 'liposomes as immunological adjuvants: antigen incorporation studies' see page 148, col. 2, second paragraph (document cited in the application)	,			International Application No	
Int. C1. 5 A61K9/127 Cinetification System Cinetification System Cinetification System Cinetification System Cinetification System Cinetification System A61K Decrimentation Statched other than State Constitution System to the Endow that such Decriments are ladded in the Fields Securical III. DOCLINGENTS CONSIDERED TO BE SELEVANT* Cinetification of Decriments 11 with indication, where appropriate, of the relevant paragraph Cinetification of Decriments 12 with indication, where appropriate, of the relevant paragraph (I EP, A, O 290 296 (THE LIPOSOME COMPANY) 9 November 1,3,4,12 2,5-11, 13,14 VACCINE vol. 5, July 1987, GUILDFORD pages 145 - 151; G. GREGORIADIS ET AL.: 'liposomes as immunological adjuvants: antigen incorporation studies' see page 148, col.2, second paragraph (document cited in the application) FR, A, 2 624 741 (INSTITUT PASTEUR) 23 June 1989 5-10,13, 14 'A' document defining the general cette of the net which is not worked in their to exhibit the relationship of the company of the property of the cited of the company of th					
Chesification System Chesification System Decrementation Extrahed where the Additional System's the Education State of the Polescent Company's the Polescent	According to L	ternational Pater	Classification (IPC) or to both National C	lassification and LPC	
Cineatification System Cineatification Symbols Decommentation Searched Symbols Decommentation Searched show than Milabram Documentation to the Relative that pack Decomments are included in the Fields Searched Standards to the Fields Searched Standards to the Fields Searched Standards Test Searched Test Searched Standards Test Searched Test Searched Standards Test Searched Standards Test Searched Test Searched Standards Test Searched Standards Test Searched Standards Test Searched Standards Test Searche	Int.Cl. 5	5 A61K9/12	7		•
Cineatification System Cineatification Symbols Decommentation Searched Symbols Decommentation Searched show than Milabram Documentation to the Relative that pack Decomments are included in the Fields Searched Standards to the Fields Searched Standards to the Fields Searched Standards Test Searched Test Searched Standards Test Searched Test Searched Standards Test Searched Standards Test Searched Test Searched Standards Test Searched Standards Test Searched Standards Test Searched Standards Test Searche					
Characteristics Systems ASIK Documentation Secreted other than Millionan Documentation to the Editor than took Disconnects are landed in the Fields Secretees EL DOCUMENTS CONSIDERED TO BE RELEVANT* Chargony* Chains of Document, III with Indication, where appropriate, of the reference parages II EP,A,O 290 296 (THE LIPOSOME COMPANY) 9 November 1, 3, 4, 12 1988 2, 5-11, 13, 14 VACCINE vol. 5, July 1987, GUILDFORD pages 145 - 151; G. GREGORIADIS ET AL.: 'liposomes as immunological adjuvants: antigen incorporation studies' see page 148, col.2, second paragraph (document cited in the application studies' see page 148, col.2, second paragraph (document cited in the application) FR,A,2 624 741 (INSTITUT PASTEUR) 23 June 1989 5-10,13, 14 *Special categories of cited Socosumits: 10 *Special categories of cited So	IL FIELDS SE	ARCHED			
Decommentation Searched where these Minimum Decommentation to the Extent that seek Decomments are landed in the Fields Searched® EEL DOCUMENTS CONSIDERED TO BE RELEVANT® Congrey® Clothon of Decommet, 12 with Indication, where appropriate, of the relevant parameters are landed in the Fields Searched® EEL DOCUMENTS CONSIDERED TO BE RELEVANT® Congrey® Clothon of Decommet, 12 with Indication, where appropriate, of the relevant parameters? EEP, A, O 290 296 (THE LIPOSOME COMPANY) 9 November 1, 3, 4, 12 2, 5-11, 13, 14 VACCINE vol. 5, July 1987, GUI(DFORD) pages 145 - 151; G. GREGORIADIS ET AL.: 'liposomes as immunological adjuvants: antigen incorporation studies' see page 148, col. 2, second paragraph (document crited in the application) FR, A, 2 624 741 (INSTITUT PASTEUR) 23 June 1989 5-10, 13, 14 *Special comparise of dired formments: 18 "A" decomment debta growth state of the surface which is seen and the principle of the applications but dired in consistent the published one or where the international filing 410 or which is crited to exhibit the published one or where the international filing 410 or which is crited to exhibit the published one or where the international filing 410 or which is crited to exhibit the published one or where the international filing 410 or which is critical to redeve the president present and critical to international filing 410 or which is critical for architection or considered to provide an international filing 410 or the Architection of published one or short the application or which the principle or theory subdiving the critical or architection or short the submitted or short the international filing 410 or the Architection of published in the original published in the critical international filing 410 or the Architection of the state part of the state p			Misles un Docume	estaction Sourchool	
Decommentation Searched other than Militimum Documentation to the Extent that such Decomments are Included in the Fields Searched III. DOCUMENTS CONSIDERED TO BE RELEVANT? Chaptery? Cleates of Decomment, III with indication, where appropriate, of the relevant paragers III Relevant to Claim Nn.III (E.P., A.O. 290 296 (THE LIPDSOME COMPANY) 9 November 1, 3, 4, 12 1988 2, 5-11. 13, 14 VACCINE vol. 5, July 1987, GUILDFORD pages 145 - 151; G. GREGORIADIS ET AL.: 'liposomes as immunological adjuvants: antigen incorporation studies' see page 148, col. 2, second paragraph (document crited in the application) FR.A, 2 624 741 (INSTITUT PASTEUR) 23 June 1989 5-10, 13, 4 see page 5 - page 6; examples 1, 6 "" Special camparise of diref formments: IP "It developes which may there doubts as printly claimfol or which is related to excellent the published on er where the international filing data for the content of the profit of the content of profit of the prof	Charification !	System		Classification Symbols	
Decomentation Searched where than Minimum Documentation to the Editor that such Decoments are incided in the Fields Searched* III. DOCUMENTS CONSIDERED TO BE RELEVANT* Chargery* Chaten of Decoment, 1" with indication, where appropriate, of the relevant passager 1" E. E. P., A., D. 290 296 (THE LIPOSOME COMPANY) 9 November 1, 3, 4, 12 1988 VACCINE vol. 5, July 1987, GUILDFORD pages 145 - 151; G. GREGORIADIS ET AL.: 'liposomes as immunological adjuvants: antigen incorporation studies' see page 148, col.2, second paragraph (document cited in the application) FR., A., 2 624 741 (INSTITUT PASTEUR) 23 June 1989 5-10, 13, 14 **Special categories of cited documents: 1" **Special ca					
III. DOCUMENTS CONSIDERED TO BE RELEVANT* Chatgory* Chains of Document, ¹³ with Indication, where appropriate, of the relevant passagers ¹² Relevant to Claim Na. ¹³ (EP, A, D 290 296 (THE LIPOSOME COMPANY) 9 November 1, 3, 4, 12 1988 (VACCINE vol. 5, July 1987, GUILDFORD pages 145 - 151; G. GREGORIADIS ET AL.: 'liposomes as immunological adjuvants: antigen incorporation studies' see page 148, col. 2, second paragraph (document cited in the application) FR, A, 2 624 741 (INSTITUT PASTEUR) 23 June 1989 *Special catagories of cited document : ¹⁵ *Ar document defining to general state of the art which is not undered to have be gradually as a second paragraph (document cited in the application) *Special catagories of cited document : ¹⁵ *Ar document defining to general state of the art which is not undered to have be gradually related to the special reserve to the state and the complete of the state of the state and the complete of the state of the state and the complete of the state of the state and the complete of the state of the state and the complete of the state of particular relevance of particular relevance the claim of the state of particular relevance of particular relevance of the claim of the state of particular relevance of particular relevance of the claim of the state of the stat	Int.C1. 5	5	A61K	· .	
III. DOCUMENTS CONSIDERED TO BE RELEVANT* Chatgory* Chains of Document, ¹³ with Indication, where appropriate, of the relevant passagers ¹² Relevant to Claim Na. ¹³ (EP, A, D 290 296 (THE LIPOSOME COMPANY) 9 November 1, 3, 4, 12 1988 (VACCINE vol. 5, July 1987, GUILDFORD pages 145 - 151; G. GREGORIADIS ET AL.: 'liposomes as immunological adjuvants: antigen incorporation studies' see page 148, col. 2, second paragraph (document cited in the application) FR, A, 2 624 741 (INSTITUT PASTEUR) 23 June 1989 *Special catagories of cited document : ¹⁵ *Ar document defining to general state of the art which is not undered to have be gradually as a second paragraph (document cited in the application) *Special catagories of cited document : ¹⁵ *Ar document defining to general state of the art which is not undered to have be gradually related to the special reserve to the state and the complete of the state of the state and the complete of the state of the state and the complete of the state of the state and the complete of the state of the state and the complete of the state of particular relevance of particular relevance the claim of the state of particular relevance of particular relevance of the claim of the state of particular relevance of particular relevance of the claim of the state of the stat					
ELIDOCLIMENTS CONSIDERED TO BE RELEVANT ⁹ Citation of Decement, ¹² vide indication, where appropriate, of the relevant parages ¹³ EP, A, D 290 296 (THE LIPOSOME COMPANY) 9 November 1, 3, 4, 12 2, 5-11, 13, 14 VACCINE vol. 5, July 1987, GUILDFORD pages 145 - 151; G. GREGORIADIS ET AL.: 'liposomes as immunological adjuvants: antigen incorporation studies' see page 148, col.2, second paragraph (document cited in the application) FR, A, 2 624 741 (INSTITUT PASTEUR) 23 June 1989 **Special compariso of cited documents: ¹⁵ **A' channes defining the growed sints of the art which is not uniform title the priority and the superiority relaxations are to confident to be of patients relaxations to their section or other special reason (as specified) **Compared which may three decoles on priority claim(s) or which is tried to considual the pullication data of an application but claims of the control of the			Documentation Sourched other to the Extent that such Documents a	than Milnimum Documentation tre Included in the Fields Searched ⁸	
Catagory* Citation of Deciment, ¹³ with indication, where appropriate, of the relevant passages ¹³ EP, A, O 290 296 (THE LIPOSOME COMPANY) 9 November 1, 3, 4, 12 2, 5-11, 13, 14 VACCINE vol. 5, July 1987, GUILDFORD pages 145 - 151; G.GREGORIADIS ET AL.: 'liposomes as immunological adjuvants: antigen incorporation studies' see page 148, col. 2, second paragraph (document cited in the application) FR, A, 2 624 741 (INSTITUT PASTEUR) 23 June 1989 5-10, 13, see page 5 - page 6; examples 1,6 "A" document defining the general cites of the set which is not membrane to be of periodic relevance in the international filling data to which is the particular relevance or which is the particular relevance or which is the particular relevance in the citation or other special relaxes (as predicted or catalists the published size of another country in the citation or other special relaxes (as predicted or catalists the published size of another country in the citation of the country of the country of the country of the country of the citation of the country of the citation of the country of the citation of the country of the country of the citation of the citation of the country of the citation of t					
Catagory* Citation of Deciment, ¹³ with indication, where appropriate, of the relevant passages ¹³ EP, A, O 290 296 (THE LIPOSOME COMPANY) 9 November 1, 3, 4, 12 2, 5-11, 13, 14 VACCINE vol. 5, July 1987, GUILDFORD pages 145 - 151; G.GREGORIADIS ET AL.: 'liposomes as immunological adjuvants: antigen incorporation studies' see page 148, col. 2, second paragraph (document cited in the application) FR, A, 2 624 741 (INSTITUT PASTEUR) 23 June 1989 5-10, 13, see page 5 - page 6; examples 1,6 "A" document defining the general cites of the set which is not membrane to be of periodic relevance in the international filling data to which is the particular relevance or which is the particular relevance or which is the particular relevance in the citation or other special relaxes (as predicted or catalists the published size of another country in the citation or other special relaxes (as predicted or catalists the published size of another country in the citation of the country of the country of the country of the country of the citation of the country of the citation of the country of the citation of the country of the country of the citation of the citation of the country of the citation of t					
**Special comporter of cited documents: 150 **A* Socrament defining the general state of the sust which is not understand the project of the particular relevance to the particular relevance cited in the publication data of another cited on the particular relevance cited in the publication data of another cited on the particular relevance cited in the publication data of another cited on the particular cited on the particular cited on the particular relevance cited in such as the patient particular relevance to the contained in the cited to examine the project particular relevance of the contained in the cited on the patient and the patient particular relevance of the contained in the contained i	III. DOCUMBO		·		
VACCINE vol. 5, July 1987, GUILDFORD pages 145 - 151; G. GREGORIADIS ET AL.: 'liposomes as immunological adjuvants: antigen incorporation studies' see page 148, col.2, second paragraph (document cited in the application) FR,A, 2 624 741 (INSTITUT PASTEUR) 23 June 1989 *Spedial categories of dited documents: 19 *Spedial cat	Category *	Citation of De	courset, 11 with indication, where appropria	ite, of the relevant passages 12	Relevant to Claim Na.13
VACCINE vol. 5, July 1987, GUILDFORD pages 145 - 151; G.GREGORIADIS ET AL.: 'liposomes as immunological adjuvants: antigen incorporation studies' see page 148, col.2, second paragraph (document cited in the application) FR,A,2 624 741 (INSTITUT PASTEUR) 23 June 1989 **Special categories of cited documents: "Special categories of cited documents: "A" document defining the general cities of the art which is net considered to be of particular previouses "It descreames the pathiched on or start the international filling date citation to other special receives or priority clainful) or which is cited to escalable the priority clainful or which is cited to escalable the priority clainful or citation to other special receive (as special col) "O" document referring to an eval discharacy of the citation of "O" document referring to an eval discharacy of the citation of "O" document of particular relevance (as special col) "O" document	x		290 296 (THE LIPOSOME C	OMPANY) 9 November	1,3,4,12
VACCINE vol. 5, July 1987, GUILDFORD pages 145 - 151; G.GREGORIADIS ET AL.: 'liposomes as immunological adjuvants: antigen incorporation studies' see page 148, col.2, second paragraph (document cited in the application) FR,A,2 624 741 (INSTITUT PASTEUR) 23 June 1989 **Special categories of cited focuments: "A" document softaing the general state of the art which is not considered to be of particular relevance. "E sealier document but published on or after the international filing date "U decrement which may three doubte on priority claim(s) or which is tried to sealable the published on er after the international filing date "U decrement referring to an ereal dischoure, use, endibition or claim our other special reston (as specified) "O" document referring to an ereal dischoure, use, endibition or claim than the priority fate claimed "A" document of particular relevance; the chimeatines "Y" decrement published prior to the International filing date but later than the priority fate claimed "A" document of particular relevance; the chimeatines "Y" decrement published prior to the International filing date but later than the priority fate claimed "Y" decrement of particular relevance; the chimeatines "Y" decrement of particular re	γ	1388			2.5-11.
vol. 5, July 1987, GUILDFORD pages 145 - 151; G.GREGORIADIS ET AL.: 'liposomes as immunological adjuvants: antigen incorporation studies' see page 148, col. 2, second paragraph (document cited in the application) FR,A,2 624 741 (INSTITUT PASTEUR) 23 June 1989 *Special categories of dited socoments: **Fractional defining the general rate of the art which is not considered to be of percentar relevance to the set which is not considered to be of percentar relevance to the set of percentar relevance to the set of percentar relevance to the set of percentar relevance to considered to be one for the set of percentage of the set of percentage	'		·		
vol. 5, July 1987, GUILDFORD pages 145 - 151; G.GREGORIADIS ET AL.: 'liposomes as immunological adjuvants: antigen incorporation studies' see page 148, col. 2, second paragraph (document cited in the application) FR,A,2 624 741 (INSTITUT PASTEUR) 23 June 1989 *Special categories of dited socoments: **Fractional defining the general rate of the art which is not considered to be of percentar relevance to the set which is not considered to be of percentar relevance to the set of percentar relevance to the set of percentar relevance to the set of percentar relevance to considered to be one for the set of percentage of the set of percentage			-		
pages 145 – 151; G. GREGORIADIS ET AL.: "Tiposomes as immunological adjuvants: antigen incorporation studies' see page 148, col.2, second paragraph (document cited in the application) FR,A,2 624 741 (INSTITUT PASTEUR) 23 June 1989 **Special categories of died focusment: 19 **A document defining the general cate of the art which is not considered to be of particular relevance of particular relevance; the claimed beautiful to understand the principle or theory and entyles of categories or particular relevance; the claimed invention categories which may throw doubts on principle or theory and entyles of categories or particular relevance; the claimed invention categories which may throw doubts on a particular relevance; the claimed invention categories or particular relevance; the claimed invention accent to except or particular relevance; the claimed invention accent to except or particular relevance; the claimed invention accent to except or particular relevance; the claimed invention accent to except or particular relevance; the claimed invention accent to except or particular relevance; the claimed invention accent to except or particular relevance; the claimed invention accent to except or particular relevance; the claimed invention accent to except or particular relevance; the claimed invention accent to except or particular relevance; the claimed invention accent to except or particular relevance; the cl	Y				2
G. GREGORIADIS ET AL.: 'liposomes as immunological adjuvants: antigen incorporation studies' see page 148, col.2, second paragraph (document cited in the application) FR.A. 2 624 741 (INSTITUT PASTEUR) 23 June 1989 See page 5 - page 6; examples 1,6 "Special categories of cited documents: 1 ¹⁰ "A" document defining the general rates of the art which is not considered to be of perform relevances "E" entire document buildhed on or after the international filling date "C" decrease which may threw doubts on priority claim(s) or which is cited to establish the publication dust of another citation or other special reason (as specified) "O" document referring to an eval direbours, use, endibities or other measures "P" decreases published prior to the international filling date but later than the priority date citized **CERTIFICATION Date of the Actual Completion of the Letterastional Search 14 JANUARY 1992 **Decrease of Authorized Officer Completion of the Letterastional Search					
immunological adjuvants: antigen incorporation studies! see page 148, col.2, second paragraph (document cited in the application) FR,A,2 624 741 (INSTITUT PASTEUR) 23 June 1989 *Special categories of cited documents: 1 ¹⁹ *A" document defining the general citric of the art which is not considered to be of particular relevance *To earlier document that published on a rater the international filing date *C" content document which may threw doubts on priority claim(s) or which is rised to establish the publication data of another citation or other means. *To document independent to an end dischouse, use, exhibition or other means. *To document independent to the international filing date but later than the priority date claimed *To document independent to the international filing date but later than the priority date claimed *To document independent to the international filing date but later than the priority date claimed *To document independent to the international filing date but later than the priority date claimed *To document independent to the international filing date but later than the priority date claimed *To document independent to the international filing date but later than the priority date claimed *To document independent to the priority date claimed *To document independent in a priority claim(s) or other precise) insure the relevance to combined with one or more other means to excellent a previous to a person skilled in the ext. *A document in combined with one or more other means and in the ext. *A document in combined with one or more other means to excellent the provious an extent excellent and the excellent threation and insure the excellent threation and insure the excellent threation of the extent excellent threating the provious and the combined threating the insure threating the provious and the combined with one or means the means				0.0	. 1
*Special categories of cited documents: 19 *A document dating the general state of the art which is not considered to be of general state of the art which is not considered to be of general state of the art which is not considered to be of general state of the art which is not considered to be of general state of an extended to be of general state of the state of an extended to be of general state of the state of particular relevance; the claimed invention cannot be considered to browless at leventies of particular relevance; the claimed invention cannot be considered to browless at leventies of particular relevance; the claimed invention cannot be considered to browless at leventies of particular relevance; the claimed invention cannot be considered to browless at leventies of particular relevance; the claimed invention cannot be considered to browless at leventies of particular relevance; the claimed invention cannot be considered to browless at leventies of particular relevance; the claimed invention cannot be considered to browless at leventies of particular relevance; the claimed invention cannot be considered to browless at leventies of particular relevance; the claimed invention cannot be considered to browless at leventies of particular relevance; the claimed invention cannot be considered to browless at leventies of particular relevance; and the principle of the same time of the same					
see page 148, col.2, second paragraph (document cited in the application) FR,A,2 624 741 (INSTITUT PASTEUR) 23 June 1989 *Special categories of cited documents: *Special categories of cited documents: *A" document defining the general state of the art which is not considered to be of perticular relevance *E" surfer document but published on or after the international filing date or which is close to establish the publication date of snacker citation or other special reason (as specified) *O" document referring to an oral directions, use, exhibition or other means *P focument published prior to the international filing date but later than the priority date claimed *V. CERTIFICATION *Date of the Actual Campletion of the International Search 14 JANUARY 1992 *Signature of Authorized Officer *Signature of Authorized Officer	•				
"Special comportee of cited documents: 19 "Special comportee of cited documents: 19 "A" document defining the general state of the art which is not considered to be of periodian relevance "E" earlier document but published on or after the international filling date considered to be of periodian relevance "I" decement which may threw doubts on priority claim(s) or which is ritted to establish the publication date of another citation or other means. "O" document referring to an oval disclosure, use, exhibition or other means. "I decement published grier to the international filling date but later than the priority date claimed. "A" document referring to an eval disclosure, use, exhibition or other means. "O" document referring to the international filling date but later than the priority date claimed. "A" document member of the same patent family "A" document member of the same patent family "A" document member of this international Search Report 14 JANUARY 1992 Date of Mailing of this International Search Report 3 0 JAN 1992		see page	148, col.2, second par	ragraph (document	
"Special categories of cited documents: 19 "Special categories of cited documents: 19 "A" document defining the general state of the art which is not considered to be or particular relevance to particular relevance to a particular relevance to the factories of the state of state and the content of particular relevance; the claimed invention cited to establish the publication date of another citation or other security special reason (as specified) "O" document referring to an eval direlective, use, exhibition or other means. "P" decoment published prior to the faternational filing date but later than the priority date claimed. Search 14 JANUARY 1992 "International Searching Authority "Signature of Authorized Officer "International Searching Authority "Signature of Authorized Officer	Y	FR,A,2 6	524 741 (INSTITUT PASTE	UR) 23 June 1989	
*Special categories of cited documents: 19 "A" document defining the general cutto of the art which is not considered to be of perticular reionance "E" surfer document but published on or after the international filing date or priority date and not its conflict with the application but cited to establish the publication date of non-the considered as perticular reionance; the claimed invention or other means "O" document referring to an oral direlessure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "A" document published prior to the international filing date but later than the priority date claimed "A" document of particular relevance; the claimed invention or cannot be considered to inventive step when the considered to inventive an inventive step when the considered to inventive step and the principle or cannot be considered to inventive step. "Y" CERTIFICATION Date of the Actual Completion of the International Search 14 JANUARY 1992 Date of Mailing of this International Search Signature of Anthorized Officer		see page	5 - page 6; examples	1,6	••
*Special categories of cited documents: 19 "A" document defining the general cutto of the art which is not considered to be of perticular reionance "E" surfer document but published on or after the international filing date or priority date and not its conflict with the application but cited to establish the publication date of non-the considered as perticular reionance; the claimed invention or other means "O" document referring to an oral direlessure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "A" document published prior to the international filing date but later than the priority date claimed "A" document of particular relevance; the claimed invention or cannot be considered to inventive step when the considered to inventive an inventive step when the considered to inventive step and the principle or cannot be considered to inventive step. "Y" CERTIFICATION Date of the Actual Completion of the International Search 14 JANUARY 1992 Date of Mailing of this International Search Signature of Anthorized Officer				-/	·
"A" document defining the general state of the art which is not considered to be of particular relevances "E" earlier decument but published on or after the international filing date "L" decement which may threw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other nexus: "P" decument published prior to the international filing date but later than the priority flate claimed "O" the Actual Completion of the International Search Oste of the Actual Completion of the International Search 14 JANUARY 1992 International Searching Authority Signature of Authorized Officer		• .	•		1
"A" document defining the general state of the art which is not considered to be of particular relevances "E" earlier decument but published on or after the international filing date "L" decement which may threw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other nexus: "P" decument published prior to the international filing date but later than the priority flate claimed "O" the Actual Completion of the International Search Oste of the Actual Completion of the International Search 14 JANUARY 1992 International Searching Authority Signature of Authorized Officer	- 1				
"A" document defining the general state of the art which is not considered to be of particular relevances "E" earlier decument but published on or after the international filing date "L" decement which may threw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other nexus: "P" decument published prior to the international filing date but later than the priority flate claimed "O" the Actual Completion of the International Search Oste of the Actual Completion of the International Search 14 JANUARY 1992 International Searching Authority Signature of Authorized Officer			<u> </u>		
"E" surfice decreasest but published on or after the international filing date "L" decreasest which may threw doubts on priority claim(s) or which is nited to exabilish the published one date of another citation or other special reason (as specified) "O" document referring to an oval dischouse, use, exhibition or other means "P" decreasest published prior to the international filing date but later than the priority date claimed "N" document referring to an oval dischouse, use, exhibition or other means "P" decreasest published prior to the international filing date but later than the priority date claimed "N" document resembler of the same of the same parameters are personally date of the actual Completion of the International Search Date of Mailing of this international Search Date of Mailing of this international Search 3 0 JAN 1992 International Searching Authority Signature of Authorized Officer		_	•	"I" later document published after the inters or selectly date and not in conflict with t	ational filing date he application but
"E" earlier document but published on or after the international filing date "L" decement which may threw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" decument published prior to the international filing date but later than the priority date claimed "A" document of particular relevance; the claimed invention cannot be exactlered to involve an inventive step when the document is combined with one or more other means, such combination being obvious to a person skilled in the art. "A" document of particular relevance; the claimed invention cannot be exactlered to involve an inventive step when the document is combined with one or more other such decument is combined with one or more other such decument is the art. "A" document of particular relevance; the claimed invention cannot be exactlered to involve an inventive step when the document is combined with one or more other such decument is combination being obvious to a person skilled in the art. "A" document of particular relevance; the claimed invention cannot be exactlered to involve an inventive and invention of comment prevents and inventive and invention and inventi	"A" documen	et defining the gen red to be of partice	eral state of the art which is not lar relevance	cited to anderstand the principle or these	y underlying the
"L" decreases which may threw doubts on priority claims or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oval dischoure, use, exhibition or other means." "P" decreases published prior to the interestional filling date but later than the priority date claimed. "CERTIFICATION Date of the Actual Completion of the Interestional Search 14 JANUARY 1992 Interestional Searching Authority Signature of Authorized Officer inventive step document of particular relevance; the claimed invention cannot be obtained in the claimed invention of particular relevance; the claimed invention cannot be obtained to inventive step "Y" document of particular relevance; the claimed invention cannot be obtained to inventive step "Y" document of particular relevance; the claimed invention cannot be obtained to inventive step "Y" document of particular relevance; the claimed invention cannot be obtained by the claimed invention of particular relevance; the claimed invention cannot be obtained to cannot be obtained by the search document of particular relevance; the claimed invention cannot be obtained in the search and its combined with one or more other such document, such combinations being obvious to a parson skilled in the art. "A" document of particular relevance; the claimed invention cannot be obtained by the combined with one or more other such document to combined with one or more other such document to combined with one or more other such document to combined with one or more other such document to combined with one or more other such document to combined with one or more other such document, such cannot be combined to com			shed on or after the interactional	"N" document of particular relevance; the cit	
Citation or other special reason (as specified) "O" shourant referring to an oval disclosure, use, exhibition or other means "P" focusions published prior to the international filing date but later than the priority date claimed "A" tocument to combination being obvious to a person skilled in the art. "A" tocument published prior to the international filing date but later than the priority date claimed "A" tocument member of the same patent family W. CERTIFICATION Date of the Actual Completion of the International Search 14 JANUARY 1992 30 JAN 1992 International Searching Authority Signature of Authorized Officer	"L" treemen	at which may three			
"O" document referring to an eval disclosure, use, exhibition or other means "P" decument gublished prior to the international filling date but later than the priority date claimed "a" document mamber of the same patent family IV. CERTIFICATION Date of the Actual Completion of the International Search 14 JANUARY 1992 Date of Mailing of this International Search 20 JAN 1992 International Searching Authority Signature of Authorized Officer				cannot be executered to involve an inven	tive step when the
"P" decument gublished prior to the interestional filing date but later than the priority date claimed "A" document number of the same patent family IV. CERTIFICATION Date of the Actual Completion of the Interestional Search 14 JANUARY 1992 3 0 JAN 1992 Interestional Searching Authority Signature of Authorized Officer			eral dischouse, use, endablities or	document is combined with one or more	other such docu-
V. CERTIFICATION Onto of the Actual Completion of the International Search 14 JANUARY 1992 3 0 JAN 1992 International Searching Authority Signature of Authorized Officer	T' (second	st published prior t		is the art.	_ `
Date of the Actual Completion of the International Search 14 JANUARY 1992 3 0 JAN 1992 International Searching Authority Date of Mailing of this International Search Report 3 0 JAN 1992	inter the	m the priority date	CUSTO	A comment segment or ma series benefit to	
14 JANUARY 1992 attractional Searching Authority Signature of Authorized Officer	IV. CERTIFICA	TION			
aturnational Searching Authority Signature of Authorized Officer	Date of the Actu	al Completice of the	be Laterasticeal Search	Date of Mailing of this International Sea	rch Report
abarasticasi Searching Authority Signature of Authorized Officer		14 JANU	IARY 1992	2 11	IAN 1992
				<u> </u>	יותן ייותן
EUROPEAN PATENT OFFICE BENZ K.F. Benz	International Sea	rching Authority			<u>. </u>
		EUROPEA	N PATENT OFFICE	BENZ K.F.	Benz

Ė

IL DOCUME	NIS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)	
atagory *	Citation of Document, with indication, where appropriate, of the relevant pursues	Relevant to Claim No.
	WO,A,9 004 412 (REGENTS OF THE UNIVERSITY OF MINNESDTA) 3 May 1990 see page 5, line 16 - line 31 see page 11, line 26 - page 13, line 22 see page 31 - page 32; example 6	11
	US,A,4 235 877 (FULLERTON) 25 November 1980 see column 3 - column 4; examples 3,5	11
	WO, A, 9 004 943 (E. UNGER ET AL) 17 May 1990 see page 48 - page 51; examples 8,9	15-19

		·
		·

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO. GB 9101547 SA 51307

This armer tists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as centained in the European Patent Office EDP file on
The European Patent Office is in no way liable for those particulars which are movely given for the purpose of information. 14/01/92

Putent decument cited in search report	Publication date	Patent family member(s)		Publication date	
EP-A-0290296	09-11-88	AU-A- AU-A- AU-A- JP-T- WO-A-	1481688 8141791 8141891 2502458 8806442	26-09-88 07-11-91 10-10-91 09-08-90 07-09-88	
FR-A-2624741	23-06-89	EP-A- WO-A-	0391962 8905631	17-10-90 29-06-89	
WO-A-9004412	03-05-90	AU-A- EP-A- CA-A-	4525589 0440742 2001737	14-05-90 14-08-91 19-01-91	
US-A-4235877	25-11-80	None			
WO-A-9004943	17-05-90	EP-A-	0442962	28-08-91	